Skip to content

TACUNA (Traditions and Connections for Urban Native Americans)

Development and Implementation of a Culturally Centered Opioid Prevention Intervention for American Indian/Alaska Native Young Adults in California

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04617938
Acronym
TACUNA
Enrollment
541
Registered
2020-11-05
Start date
2020-11-23
Completion date
2025-07-28
Last updated
2026-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol Drinking, Marijuana Use, Opioid Use

Keywords

American Indian/Alaska Native young adults, Cultural intervention, Motivational interviewing

Brief summary

This study responds to Request For Application-DA-19-035, HEAL (Helping End Addiction Long Term) initiative: Preventing OUD in Older Adolescents and Young Adults (ages 16-30) by developing and implementing a culturally centered intervention to address opioid use among urban AI/AN emerging adults in California. The primary goal of this study is to compare AI/AN emerging adults who receive TACUNA plus a Wellness Circle (WC) to those AI/AN emerging adults who receive an opioid education workshop on outcomes (e.g., opioid misuse and alcohol and other drug use) over a period of 12 months. TACUNA will be a motivational interviewing group intervention that incorporates traditional practices and discussion of how to cultivate healthy social networks and cultural worlds. The Wellness gathering will be for emerging adults and people in their social network, and will focus on how social networks and cultural connectedness influence healthy behaviors. Opioid education will focus on discussion of opioid misuse within the AI/AN urban community and ways to reduce use in a culturally appropriate manner. Investigators expect those who receive TACUNA + WG will report less opioid and AOD (alcohol and other drug) use frequency, fewer consequences, less time spent around peers who use opioids and AOD, and less perceived prevalence of peer use compared to opioid education over a period of 12 months. Also, investigators will evaluate the intervention's effects on secondary outcomes of social networks and cultural connectedness. Survey data is collected at baseline, 3-months, 6-months and 12-months. Longitudinal analyses will compare intervention participant and control participants on primary and secondary outcomes.

Detailed description

Data from 2015 show that American Indians/Alaska Natives (AI/ANs) have the highest rates of diagnosis for opioid use disorders (OUD) and deaths from drug overdose. Misuse of prescription opioids, defined here as taking opioid medications in a manner or dose other than prescribed or for hedonic effects, and the use of heroin, have emerged as major public health concerns in the United States. Of particular concern is the prevalence of opioid use among emerging adults (ages 18-25) as this is a developmental period of heightened vulnerability and critical social, neurological, and psychological development. Unique risk factors may predispose urban AI/AN young adults to use opioids, alcohol or other drugs. For example, experiences of acculturative stress directly and indirectly associated with historical trauma experienced by AI/ANs throughout U.S. history result in poor health outcomes. One U.S. law that has been postulated to contribute to various health disparities among urban AI/ANs is the Relocation Act of 1956. This Act financed the relocation of individual AIs and AI families to job training centers in designated U.S. cities. Rather than establishing economic stability, large numbers of AIs who moved to urban areas became unemployed, homeless, and disconnected from their community-based support networks. This relocation appears to have contributed to an inter-generational effect whereby successive generations of urban AIs and ANs continue to experience various health-related disparities. Our work with urban AI/AN adolescents highlighted that many experience stress related to identity in the form of both subtle (e.g., being asked whether one is a "real" Indian) and overt (e.g., being called a racist name like Squaw or Red Skin) discrimination. Programming that incorporates traditional practices, promotes community involvement, and encourages healthy notions of AI/AN identity may increase well-being and healthy behaviors by addressing sources of stress linked to cultural identity, stigma, and community connections. However, few evidence-based programs that integrate these cultural elements have been developed, implemented, and evaluated with urban AI/AN using a strong research design. The current study substantially extends work with AI/AN emerging adults by adapting and testing an integrated culturally appropriate MI and social network intervention to address opioid and other AOD (alcohol and other drug) misuse at both the individual and community level.

Interventions

BEHAVIORALTACUNA plus Wellness Circle

TACUNA provides three virtual workshops (one hour each) that use motivational interviewing and a virtual Wellness Circle (WC). The workshops combine a 30-minute discussion of opioid, alcohol and marijuana use, and social networks with another 30 minutes focused on three different traditional practices (one per workshop). TACUNA was adapted from our three-session workshop, MICUNAY (Motivational Interviewing and Culture for Urban Native American Youth) protocol, which was developed and tested for urban AI/AN adolescents and from focus groups conducted in Year 1. For the Wellness Circle, youth will have members of their social network virtually attend these once-a-month gatherings. The WC will bring people together to celebrate health and wellness and tradition. The WC will focus on the importance of social networks in making healthy choices, and provide discussion on the role that AOD use and engagement in traditional practices among members of their social networks affect their choices.

BEHAVIORALOpioid Education Workshop

The virtual opioid education workshop draws from prevention and education materials supplied and recommended by the National AI/AN Technology and Transfer Center, which is funded by SAMHSA. Materials are culturally relevant educational packages addressing opioid use through recorded webinars, toolkits, and other resources.

Sponsors

RAND
Lead SponsorOTHER
University of California, Los Angeles
CollaboratorOTHER
Sacred Path Indigenous Wellness Center
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 25 Years
Healthy volunteers
Yes

Inclusion criteria

* must self-identify as American Indian/Alaska Native (AI/AN) * be in the age range of 18-25 * not be in need of substance treatment

Exclusion criteria

* If substance treatment need is indicated

Design outcomes

Primary

MeasureTime frameDescription
Alcohol Use Past 3 Months3, 6, and 12 months post-baselineSurvey asks number of times had "At least one drink of alcohol." Response was on a scale with options 0=none, 1=1 time, 2=2 times, 3=3-5 times, 4=6-9 times, 5=10-19 times, 6=20-30 times, and 7=31+ times. Responses were translated to actual number of times by taking the midpoints of intervals, e.g. response 3 ("3-5 times") coded as 4 times. To be conservative values were rounded down when the midpoint was not an integer, e.g. response 4 ("6-9 times") coded as 7 times. Response 7 ("31+ times") was coded as 31 times.
Cannabis Use Past 3 Months3, 6, and 12 months post-baselineSurvey asks how many times participant used "Marijuana (cannabis, pot, weed, hash)." Response was on a scale with options 0=none, 1=1 time, 2=2 times, 3=3-5 times, 4=6-9 times, 5=10-19 times, 6=20-30 times, and 7=31+ times. Responses were translated to actual number of times by taking the midpoints of intervals, e.g. response 3 ("3-5 times") coded as 4 times. To be conservative values were rounded down when the midpoint was not an integer, e.g. response 4 ("6-9 times") coded as 7 times. Response 7 ("31+ times") was coded as 31 times.
Most Drinks in One Day During the Past Month3, 6, and 12 months post-baselineIf participant reports any drinks in past month, survey asks "What is the largest number of drinks you had on any day in the PAST MONTH (30 DAYS)?" Response options range from 1 (a few sips) to 17 (15 or more drinks)
Amount of Cannabis Used Per Day When Using3, 6, and 12 months post-baselineParticipants reporting lifetime marijuana use were asked "On the days you use marijuana, about how much marijuana flower/bud do you personally consume?" with response options ranging from 1="less than 0.25g" to 10="more than 5g."
Opioid Use Past 3 Months3, 6, and 12 months post-baselineMeasure Description: Survey asks number of times used "Prescription opioid." Response was on a scale with options 0=none, 1=1 time, 2=2 times, 3=3-5 times, 4=6-9 times, 5=10-19 times, 6=20-30 times, and 7=31+ times. Responses were translated to actual number of times by taking the midpoints of intervals, e.g. response 3 ("3-5 times") coded as 4 times. To be conservative values were rounded down when the midpoint was not an integer, e.g. response 4 ("6-9 times") coded as 7 times. Response 7 ("31+ times") was coded as 31 times.

Secondary

MeasureTime frameDescription
Cultural Connectedness3, 6, and 12 months post-baselineMeasured using the Sense of Community Index-2. Mean of 24 items about AI/AN communities (example: "I get important needs of mine met because I am part of this community") with response options ranging from 0=not at all to 3=completely, with higher values indicating a greater sense of community

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORElizabeth D'Amico, PhD

RAND

PRINCIPAL_INVESTIGATORDaniel Dickerson, DO, MPH

UCLA Integrated Substance Abuse Programs

Participant flow

Pre-assignment details

Flow info is for Phase 2 (P2) only. Phase 1 (P1, discovery phase) informed P2 (clinical trial phase) via focus groups of participants that were not part of the P2 clinical trial. Parents & providers--all lacking eligibility in the clinical trial--also participated in P1 focus groups. No NCT# was created for P1 as it was not an RCT phase. Additionally, P1 was funded under a separate NIH award number (UG3DA050235) and recruited under a separate IRB protocol. P2 funding award number: UH3DA050235.

Baseline characteristics

Characteristic
Age, Continuous22.09 years
STANDARD_DEVIATION 2.19
Alcohol Use Past 3 Months8.78 drink events
STANDARD_DEVIATION 10.43
Amount of cannabis used per day when using2.90 units on a scale
STANDARD_DEVIATION 2.82
Cannabis use past 3 months10.62 marijuana use events
STANDARD_DEVIATION 13.04
Cultural connectedness1.64 units on a scale
STANDARD_DEVIATION 0.62
Ethnicity (NIH/OMB)
Hispanic or Latino
152 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
191 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Most drinks in one day during the past month7.13 units on a scale
STANDARD_DEVIATION 3.61
Opioid Use Past 3 Months0.17 opioid use events
STANDARD_DEVIATION 1.6
Race (NIH/OMB)
American Indian or Alaska Native
165 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
2 Participants
Race (NIH/OMB)
More than one race
94 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
1 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
0 Participants
Region of Enrollment
United States
541 participants
Sex: Female, Male
Female
233 Participants
Sex: Female, Male
Male
46 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 2790 / 262
other
Total, other adverse events
79 / 27983 / 262
serious
Total, serious adverse events
0 / 2790 / 262

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 13, 2026